Press release
Non-Alcoholic Steatohepatitis Treatment Market Growth, Key Drivers, Segmentation, And Forecast To 2033
Non-Alcoholic Steatohepatitis Treatment Market
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
According to The Business Research Company's, The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $1.89 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 38.7%. The growth in the historic period can be attributed to rising prevalence of nash, growing awareness and diagnosis, lifestyle changes and obesity epidemic, clinical research, healthcare infrastructure and access, regulatory support and clinical trials.
The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $9.89 billion in 2028 at a compound annual growth rate (CAGR) of 39.4%. The growth in the forecast period can be attributed to advancements in drug development, increased disease awareness, rising prevalence and risk factor, shift towards personalized medicine. Major trends in the forecast period include patient-centric approach, technological advancements, targeted therapies, regulatory landscape, advancements in research.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report
Market Drivers and Trends:
The increasing cases of obesity are expected to boost the growth of the non-alcoholic steatohepatitis treatment market going forward. Obesity refers to a medical condition characterized by the excessive accumulation of body fat, often resulting in an individual having a body mass index (BMI) of 30 or higher, and is associated with various health risks and complications. The increasing prevalence of obesity worldwide has led to a rise in the incidence of NASH, making it potentially the most common cause of advanced liver disease. For instance, in March 2022, according to the World Health Organization, a Switzerland-based public health organization, over 1 billion individuals globally were affected by obesity, comprising 650 million adults, 340 million adolescents, and 39 million children, with this figure continuing to rise. The World Health Organization (WHO) projects that by 2025, around 167 million people, encompassing both adults and children, will experience compromised health due to being overweight or obese. Therefore, the increasing cases of obesity are driving the growth of the non-alcoholic steatohepatitis treatment market.
The development of the non-alcoholic steatohepatitis (NASH) drug is a key trend gaining popularity in the non-alcoholic steatohepatitis treatment market. Many companies are investing in developing innovative drugs for the treatment of liver diseases with reduced side effects of the drugs. For instance, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology company, received a grant from U.S. Food and Drug Administration (FDA) for fast-track designation to facilitate the development of the non-alcoholic steatohepatitis (NASH) drug, namely ervogastat and clesacostat. Fast Track is a process designed to Pfizer's investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis named as; ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Major Key Players of the Market:
AstraZeneca Plc, Tobira Therapeutics Inc., Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Conatus Pharmaceuticals Inc., Novo Nordisk A/S, Immuron Ltd., Raptor Pharmaceutical Corp., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Gemphire Therapeutics Inc., Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Sinew Pharma Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG, Asahi Kasei Corporation
Non-Alcoholic Steatohepatitis Treatment Market 2024 Key Insights:
• The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $9.89 billion in 2028 at a compound annual growth rate (CAGR) of 39.4%.
• Insulin Resistance Surge Fueling Growth In The Non-Alcoholic Steatohepatitis Treatment Market
• Advancements In Non-Alcoholic Steatohepatitis (NASH) Drug Development Transforming Treatment Landscape
• North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=8595&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis Treatment Market Growth, Key Drivers, Segmentation, And Forecast To 2033 here
News-ID: 3742387 • Views: …
More Releases from The Business Research Company
n-Butanol Market to Grow at 5% CAGR, Reaching $4.52 Billion by 2029
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
n-Butanol Market Outlook: How is the Market Expected to Grow by 2025?
The market size for n-butanol has been experiencing a consistent growth in the past few years. The market is projected to expand from $3.55 billion in 2024 to $3.72 billion in 2025, demonstrating a Compound Annual Growth Rate…
Acrylic Powder Coating Market is Anticipated to Expand upto $1.98 Billion in 202 …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What Is the Forecasted Market Growth Rate of the Acrylic Powder Coating Industry?
The market for acrylic powder coating has seen sustained growth over the past few years. Expectations are for it to expand from a value of $1.53 billion in 2024 to $1.6 billion in 2025, reflecting a 4.5% compound…
L-lactide Industry Expected to Reach $2.64 Billion by 2029 at 12.7% CAGR
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
L-lactide Market Value Projection: How Much Will the Market Size by 2025?
The market size for l-lactide has experienced quick expansion in the past few years. The value is projected to increase from $1.45 billion in 2024 to $1.63 billion in 2025, representing a compound annual growth rate (CAGR) of 12.6%.…
Graphene Market is Anticipated to Expand upto $3.41 Billion in 2029
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What Is the Forecasted Market Growth Rate of the Graphene Industry?
In the latest years, the size of the graphene market has seen a substantial expansion. It is projected that it will rise from $1.32 billion in 2024 to $1.6 billion in 2025, with a compound annual growth rate (CAGR) of…
More Releases for Steatohepatitis
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.67 billion In 2028…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
